Skip to content

Post-osteoporotic Fracture Exercise Program

Community Osteoporosis Exercise Class for People Post Fracture

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07595991
Enrollment
100
Registered
2026-05-19
Start date
2026-09-01
Completion date
2028-02-01
Last updated
2026-08-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoporosis, Osteoporotic Fracture

Keywords

Osteoporosis, Exercise Intervention, Osteoporotic fracture

Brief summary

Those with osteoporosis often have weaker bones and this leads to higher chances of fractures. Therefore, the investigators want to evaluate the feasibility and safety of group exercise classes specifically designed for individuals with osteoporosis who had an osteoporotic fracture. By focusing on this high-risk population, the investigators want to see whether such exercise interventions can be an option for improving bone health, reducing the risk of future fractures, and enhancing physical function without compromising safety.

Interventions

OTHERExercise Program

Participants complete a 12-week, twice weekly, whole body group exercise program. Participants will also complete qualitative interviews and DXA bone scans.

Sponsors

Western University, Canada
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Diagnosed with osteoporosis. * History of low trauma fracture within the past year * Cleared for physical activity using the get active questionnaire, 100 bpm resting heart rate or less, 160 mm Hg diastolic blood pressure or less * Able to understand and provide informed consent. * Residing within the study's geographic area (e.g., London, Ontario).

Exclusion criteria

* Individuals who do not understand the English language * Medical conditions contraindicating participation in exercise (e.g., uncontrolled cardiovascular disease, severe respiratory illness). * Cognitive impairments that prevent informed consent or participation. * Recent major surgeries or medical events limiting physical activity. * Participation in conflicting clinical trials or rehabilitation programs. * Residents outside the designated study area.

Design outcomes

Primary

MeasureTime frameDescription
Recruitment FeasibilityAssessed over 12 monthsRecruitment feasibility will be assessed by the number of participants enrolled in the study over a 12-month recruitment period. The target recruitment goal is 100 participants.
Retention FeasibilityAssessed at 12 weeksRetention feasibility will be assessed as the percentage of enrolled participants who complete the 12-week reassessment. The predefined retention target is 60%. Percentages range from 0% to 100%, with higher percentages indicating better retention feasibility.
Exercise Class AdherenceAssessed over the 12-week intervention periodExercise adherence will be assessed using class attendance records. Adherence will be calculated as the percentage of scheduled exercise sessions attended by each participant. The predefined adherence target is 80%. Percentages range from 0% to 100%, with higher percentages indicating better adherence.

Secondary

MeasureTime frameDescription
Program AcceptabilityAssessed at 12 weeksProgram acceptability will be assessed using participant exit interviews conducted at the completion of the intervention. Acceptability will be calculated as the percentage of participants who report a positive response regarding satisfaction with the program. The predefined acceptability target is 80%. Percentages range from 0% to 100%, with higher percentages indicating greater program acceptability.
Intervention SafetyAssessed throughout the 12-week intervention periodIntervention safety will be assessed by recording the number and type of adverse events attributable to the intervention, including falls, musculoskeletal pain, prolonged muscle soreness, dizziness, fainting, shortness of breath, and other participant-reported medical concerns. Lower numbers indicate better intervention safety.

Countries

Canada

Contacts

CONTACTChristina Ziebart, PT, PhD
cziebart@uwo.ca519-661-2111
CONTACTAbigail Mitchell, BSc
amitc57@uwo.ca709-727-2762

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 21, 2026